Sunday - October 19, 2025

Treg Cell-Based Therapies Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Rapa Therapeutics, Orca Bio, Caladrius Biosciences, Sangamo Therapeutics, Quell Thera

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Treg Cell-Based Therapies pipeline constitutes key 51+ companies continuously working towards developing 55+ Treg Cell-Based Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading

Synovial Sarcoma Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Advenchen Lab, Ipsen, Daiichi Sankyo, OncoTherapy Science, Foghorn Therapeutics, BioAtla

The Key Synovial Sarcoma Companies in the market include – Advenchen Laboratories, Ipsen, Daiichi Sankyo, OncoTherapy Science, Foghorn Therapeutics, BioAtla, Inc., Takara Bio, C4 Therapeutics, Adaptimmune, Epizyme, Inc., and others.   The Synovial Sarcoma market is expected to surge due … Continue reading

Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross

The Key Sarcopenia Companies in the market inlcude- TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others.   DelveInsight’s “Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034″ … Continue reading

Night Vision Disturbances Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Ocuphire Pharma, Viatris

The Key Night Vision Disturbances Companies in the market include – Ocuphire Pharma/Viatris, and others.   DelveInsight’s “Night Vision Disturbances Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Night Vision Disturbances, historical and forecasted epidemiology … Continue reading

Psoriasis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Biosciences, Aclaris Therapeutics, AbbVie

The Key Psoriasis Companies in the market inlcude – UCB Pharma, Novartis, Sun Pharmaceutical/ Almirall, Bausch Health, Boehringer Ingelheim, LEO Pharma, AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma, E-nitiate Biopharmaceuticals, SFA Therapeutics, Rubedo Life Sciences, Inc, and others.   DelveInsight’s … Continue reading

Gout Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight

DelveInsight’s “Gout Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Gout pipeline landscape. It covers the Gout Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gout Pipeline … Continue reading

Beta Thalassemia Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight

DelveInsight’s “Beta Thalassemia Pipeline Insight 2025” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Beta Thalassemia pipeline landscape. It covers the Beta Thalassemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading

Hereditary Transthyretin Amyloidosis Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight

DelveInsight’s “Hereditary Transthyretin Amyloidosis Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Hereditary Transthyretin Amyloidosis pipeline landscape. It covers the Hereditary Transthyretin Amyloidosis Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading

Hypercholesterolemia Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight

DelveInsight’s, “Hypercholesterolemia Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Hypercholesterolemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product … Continue reading

Influenza Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight

DelveInsight’s “Influenza Pipeline Insight 2025” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Influenza pipeline landscape. It covers the Influenza Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Influenza Pipeline … Continue reading